ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 19 Dec 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease in patients who fulfil the following criteria:
    • Have a corneal fluorescein staining (CFS) grade of 4 using the modified Oxford scale or equivalent; AND
    • Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease in patients who fulfil the following criteria; AND
    • Inadequate symptom control using optimised treatment with tear substitutes for at least 3 months.

in view of acceptable proposal from the company.

Funding status

Ciclosporin 0.1% eye drops, the only licensed ciclosporin eye preparation registered with the Health Sciences Authority, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 February 2023.

MAF assistance does not apply to other strengths or extemporaneous preparations of ciclosporin eye drops.


Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease (19 December 2022)